Lead Product(s) : Dupilumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent (dupilumab), a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways, reduced COPD exacerbations in Phase 3 trial.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
November 27, 2023
Lead Product(s) : Dupilumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 3 trial showed Dupixent® (dupilumab) significantly reduced severe asthma attacks, and within two weeks rapidly improved lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma, with evidence of type 2 inflammation.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
May 17, 2021
Lead Product(s) : Dupilumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Masitinib Mesylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 3 study evaluating AB1010, oral masitinib at 6 mg/kg/d versus placebo in severe asthma uncontrolled by oral corticosteroids met its primary endpoint. Masitinib decreased the rate of severe asthma exacerbations in patients with severe asthma uncontr...
Product Name : AB1010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2022
Lead Product(s) : Masitinib Mesylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Masitinib Mesylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AB Science Announces Positive Top-Line Phase 3 Results for Oral Masitinib in Severe Asthma
Details : The pre-specified primary analysis was rate of severe asthma exacerbations, with masitinib demonstrating a statistically significant 29% reduction in severe exacerbations relative to placebo.
Product Name : AB1010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2020
Lead Product(s) : Masitinib Mesylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Masitinib Mesylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Masitinib selectively targets mast cells through inhibition of tyrosine kinases c-Kit, LYN and FYN. Phase 3 study (AB07105) evaluating oral masitinib at 6 mg/kg/day versus placebo in severe asthma uncontrolled by oral corticosteroids (OCS) met its primar...
Product Name : AB1010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2020
Lead Product(s) : Masitinib Mesylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Masitinib Mesylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Masitinib is a first in class oral drug in severe asthma, selectively targeting mast cells through inhibition of tyrosine kinases c-Kit, LYN and FYN.
Product Name : AB1010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2020
Lead Product(s) : Masitinib Mesylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Masitinib Mesylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted AB Science phase 3 study AB07015 results with masitinib in severe asthma.
Product Name : AB1010
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 05, 2020
Lead Product(s) : Masitinib Mesylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable